Invex Therapeutics Ltd. Stock Analysis IXC.AX

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Perth, Western Australia. The company went IPO on 2019-07-05. The firm is focused on the repurposing of an already-approved drug, Exenatide, for the efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP). In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. The principal activity of the Company is the development of Exenatide, including generating new pre-clinical data in Alzheimer’s Disease (AD) under a collaboration with Tessara Therapeutics. The firm has trademarked its repurposed Exenatide as Presendin. The firm is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.